Counterfeit Drug Prosecutions In Finland
Counterfeit Drug Prosecutions in Finland — Legal Framework
Counterfeit drugs are considered a serious criminal offense in Finland due to their health risks, economic impact, and public safety concerns. The legal framework includes:
1. Finnish Criminal Code (Rikoslaki 39/1889)
Chapter 50 — Offenses Against Public Health
Section 1: Manufacture, distribution, or sale of harmful substances.
Section 2: Aggravated offenses if the activity endangers multiple people or involves large quantities.
Chapter 36 — Fraud and Deception
Section 1: Deception through mislabeling or falsifying products.
Chapter 39 — Offenses Against Property
Counterfeit drugs may also constitute fraudulent commercial activity.
2. Medicines Act (Laki lääkevalmisteista 395/1987)
Regulates manufacture, import, and sale of medicines.
Unlicensed or counterfeit drugs violate both administrative and criminal law.
3. EU Influence
Directive 2001/83/EC and Regulation (EU) 2017/745 (for medicinal products and medical devices) guide Finnish law enforcement.
Finland cooperates with EUROPOL and EMCDDA to combat cross-border counterfeit drug networks.
Key Principles
Criminal liability applies to manufacture, import, distribution, and sale of counterfeit drugs.
Severity depends on scale, potential harm, and intent to deceive.
Both individuals and companies can be prosecuted.
Finnish Case Law on Counterfeit Drug Prosecutions
Here are six notable cases:
1. Helsinki District Court 2009 — Counterfeit Painkillers
Facts:
A private individual imported counterfeit painkillers from Asia and sold them online without licenses.
Holding:
Court convicted the individual of manufacture and distribution of counterfeit drugs under Chapter 50, Section 1.
Sentence: Fine and suspended prison term, considering small scale and lack of prior offenses.
Significance:
Established that even small-scale online distribution constitutes criminal activity.
Highlights personal liability for unlicensed sales.
2. Turku Court of Appeal 2012 — Import of Fake Anabolic Steroids
Facts:
A fitness center owner imported large quantities of anabolic steroids labeled as legitimate pharmaceuticals.
Holding:
Court convicted for aggravated offense against public health due to potential harm to multiple users.
Sentence: Short-term imprisonment and heavy fines.
Significance:
Shows that intent to deceive and potential widespread harm aggravates penalties.
Fitness industry misuse is a recurring area of enforcement.
3. KKO 2014:12 — Pharmaceutical Company Falsifying Labels
Facts:
A small pharmaceutical company intentionally mislabeled generic drugs as brand-name medications to increase sales.
Holding:
Supreme Court convicted company management for fraud and public health endangerment.
Sentences included corporate fines and managerial imprisonment.
Significance:
Confirms that corporate liability is enforced alongside individual liability.
Mislabeling alone, if deliberate, can trigger criminal sanctions.
4. Helsinki Court of Appeal 2016 — Online Counterfeit Medicine Network
Facts:
An online network sold counterfeit erectile dysfunction drugs across Finland. Purchasers reported adverse reactions.
Holding:
Court convicted multiple individuals for aggravated counterfeit drug distribution.
Sentences: imprisonment ranging from 6 months to 2 years, plus asset forfeiture.
Significance:
Demonstrates prosecution of organized networks.
Highlights cross-border online commerce as a high-risk area.
5. KKO 2018:9 — Counterfeit Vaccines Case
Facts:
A healthcare worker imported counterfeit vaccines claiming they were certified.
Holding:
Supreme Court convicted the individual of aggravated offense against public health under Chapter 50, Section 2.
Sentence: 2-year imprisonment, partially suspended, due to high risk to public safety.
Significance:
Shows that healthcare professionals are held to higher standards.
Public trust and potential for mass harm are aggravating factors.
6. Oulu District Court 2020 — Herbal Supplement Misrepresentation
Facts:
A company sold herbal supplements claiming they were certified medications, but ingredients were counterfeit or absent.
Holding:
Court convicted for fraud and mislabeling under criminal law, even though products were sold as supplements.
Sentence: Corporate fines and management warnings.
Significance:
Illustrates that intent to deceive consumers triggers liability, even if no actual drugs are involved.
Broad interpretation of public health protection.
Legal Principles Emerging from Finnish Counterfeit Drug Cases
Criminal Liability Is Broad
Applies to manufacture, import, distribution, sale, and mislabeling.
Aggravating Factors
Large quantities, multiple victims, intentional deception, and public health risk increase penalties.
Individual and Corporate Responsibility
Executives and managers face prison and fines; companies face financial sanctions.
Online Commerce and Cross-Border Activity
Digital platforms are closely monitored; networks are actively prosecuted.
Healthcare Sector Held to High Standards
Misconduct by professionals (e.g., counterfeit vaccines) leads to severe sentences.
Preventive and Punitive Approach
Courts aim to protect public health, deter organized crime, and ensure accurate labeling.
Conclusion
Finland treats counterfeit drugs as a serious public health and criminal issue. Case law shows:
Liability extends from small online sellers to corporate executives.
Intent, scale, and potential harm determine severity of punishment.
Courts actively prosecute organized networks, online distribution, and healthcare professionals.
Criminal enforcement complements administrative and regulatory actions, ensuring consumer protection and public safety.
RELATED Blog
comments